Increased investment spurs advances in gene therapy
![](/46/pdcnewsitem/03/84/23/Frost.jpg)
The success of approved products for rare illnesses has opened the door for gene-based treatments of more prevalent diseases, finds Frost & Sullivan.
Currently, gene therapy is recovering across the biopharmaceutical industry as the quality and effectiveness of the technology shows gradual, but marked improvement. While safety concerns during the nascent phases affected technology adoption, novel delivery vector systems have facilitated the development of numerous safe therapeutic solutions and have given the technology a second wind.
Analysis from Frost & Sullivan, Advances in Gene Therapy, finds gene therapy can be effective for several emerging disease groups, including ocular diseases, diabetes, infectious illnesses and many of cancer types. Gene therapy for rare genetic diseases has been the most fruitful in terms of clinical trials. The success of these niche therapeutics has paved the way for similar applications for additional widespread diseases.
Until now, adverse side effects, as well as high costs, had made regulatory bodies and patients skeptical about gene therapy, while health insurance companies had been reluctant to provide reimbursements.
However, an increasing number of collaborations among research and pharmaceutical companies to understand the potential applicability of gene therapy for prevalent diseases, such as cancer, will help develop novel and approved modes of treatment.
"With the rise in clinically proven remedies, it is likely insurance companies will begin to acknowledge the commercial advantage of gene therapy," said TechVision Senior Research Analyst Madhumitha Rangesa.
Improvements in vector technology and delivery systems will further enhance efficacy and clinical outcomes. Currently, the ocular diseases space is witnessing a rapid influx of companies equipped with the appropriate vector delivery systems capable of carrying small gene loads to specific target sites in the human body.
The use of combination therapies is another novel idea that will boost the therapeutic effects of gene technology. Competing industries, like cancer immunotherapy, are already shifting towards combination therapies within their own industry, with conventional or other burgeoning therapeutic fields.
Once the gene therapy industry bounces back with noteworthy products, governments around the world will step in to accelerate innovation. In the U.S., the growing emphasis on precision medicine capable of catering to a specific subset of people based closely on their genetic makeup is widening the scope for gene-based therapeutics.
"North America has the highest number of clinical trials in gene therapy largely due to the extensive focus on innovation and availability of funding," noted Rangesa. "In terms of market commercialization, Europe has overtaken North America with two products approved for commercialization within Europe and one approved for commercialization globally; however Asia is slowing catching up."
The global interest in the technology will attract investments and support the evolution of gene-based remedies from production and clinical trials to commercialization.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance